Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Author(s): Kevin Kalinsky, MD, MS¹; Melissa K. Accordino, MD, MS²; Codruta Chiuzan, PhD³; Prabhjot S. Mundi, MD²; Elizabeth Sakach, MD¹; Claire Sathe, MD²; Heejoon Ahn, MS³; Meghna S. Trivedi, MD, MS²; Yelena Novik, MD⁴; Amy Tiersten, MD⁵; George Raptis, MD⁶; Lea N. Baer, MD⁷; Sun Y. Oh, MD⁸; Amelia B. Zelnak, MD⁹; Kari B. Wisinski, MD¹⁰; Eleni Andreopoulou, MD¹¹; William J. Gradishar, MD¹²; Erica Stringer-Reasor, MD¹³; Sonya A. Reid, MD¹⁴; Anne O’Dea, MD¹⁵; Ruth O’Regan, MD¹⁶; Katherine D. Crew, MD, MS²; and Dawn L. Hershman, MD, MS²

Source: DOI: 10.1200/JCO.22.02392 Journal of Clinical Oncology

Dr. Anjan Patel's Thoughts

Interesting approach where endocrine therapy was changed after progression on 1L therapy and the ribociclib was continued.

PURPOSE

Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer (MBC). Although preclinical and clinical data demonstrate a benefit in changing ET and continuing a CDK4/6i at progression, no randomized prospective trials have evaluated this approach.

METHODS

In this investigator-initiated, phase II, double-blind placebo-controlled trial in patients with HR+/HER2– MBC whose cancer progressed during ET and CDK4/6i, participants switched ET (fulvestrant or exemestane) from ET used pre-random assignment and randomly assigned 1:1 to the CDK4/6i ribociclib versus placebo. PFS was the primary end point, defined as time from random assignment to disease progression or death. Assuming a median PFS of 3.8 months with placebo, we had 80% power to detect a hazard ratio (HR) of 0.58 (corresponding to a median PFS of at least 6.5 months with ribociclib) with 120 patients randomly assigned using a one-sided log-rank test and significance level set at 2.5%.

RESULTS

Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006. At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.

CONCLUSION

In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2– MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.

Author Affiliations

¹Winship Cancer Institute, Emory University, Atlanta, GA²Columbia University Irving Medical Center, New York, NY³Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY⁴New York University Perlmutter Cancer Center, NYU Langone Health, New York, NY⁵Icahn School of Medicine at Mount Sinai, New York, NY⁶Zucker School of Medicine—Northwell Cancer Institute, Lake Success NY⁷State University of New York at Stony Brook, Stony Brook, NY⁸Montefiore Medical Center, Bronx, NY⁹Northside Hospital, Atlanta, GA¹⁰University of Wisconsin Carbone Cancer Center, Madison, WI¹¹Weill Cornell Medicine, New York, NY¹²Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL¹³University of Alabama, Birmingham, Birmingham, AL¹⁴Vanderbilt University Medical Center, Nashville, TN¹⁵University of Kansas Medical Center, Westwood, KS¹⁶University of Rochester Medical Center, Rochester, NY

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Primary objective not met, ctDNA clearance post- neoadjuvant therapy (NAT) cannot reliably predict pathologic complete response (pCR) and shouldn't be used to defer surgery. But the prognostic data are striking: post-NAT ctDNA positivity independently predicted recurrence in triple-negative breast cancer (TNBC) (HR 8.9), and the postsurgical landmark analysis is essentially binary, 100% of ctDNA-positive patients recurred while 94% of ctDNA-negative patients were disease-free at 5 years (HR 128). Not practice-changing yet pending prospective utility trials, but this strongly validates ultrasensitive ctDNA as a prognostic tool and a smart enrollment biomarker for future escalation/de-escalation trials.

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway. PFS was 9.3 m in the gedatolisib-triplet group vs 2.0 m in the fulvestrant group (hazard ratio) HR 0.24, and 7.4 m in the gedatolisib-doublet group HR 0.33 v fulvestrant.

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

This is impressive. However, there is no reported placebo trastuzumab deruxtecan arm, so this is not truly a “no chemotherapy” regimen. It is important to remember that deruxtecan is itself a chemotherapy agent. So, this is really comparing deruxtecan vs taxol or more accurately, a comparison of chemotherapy delivery systems.

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial

The QUIWI study used quizartinib, a FLT3 drug added to standard chemo induction/consolidation in FLT-negative acute myeloid leukemia (AML) patients. There was a meaningful overall survival (OS) improvement across all age and risk groups including the NPM1+ population. They purposefully used a higher dose to achieve what is felt to be off-target TKI activity in familiar pathways of KIT, PDGRF…etc.

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

This really feels like a first-line practice changer in PD-L1+ MTNBC—the sacituzumab govitecan/pembrolizumab combination delivering a 3.4-month progression-free survival (PFS) improvement and pushing median PFS past 11 months is quite meaningful. Mature overall survival (OS) data will be interesting to see. Remember to watch closely and consider screening for drug-induced interstitial lung disease(ILD).